NAFDAC: New Fake Drug Reporting Channels Launched in Nigeria

• NAFDAC has established multiple channels for Nigerians to report suspected fake, substandard, or unregistered medicines and adverse drug reactions.
• The MedSafety app is available for reporting adverse reactions to medicines, vaccines, or other regulated medical products.
• Suspected fake or substandard medical products can be reported via the NAFDAC Greenbook app or its corresponding web platform.
• Consumers can verify a product's registration status using the NAFDAC Automated Product Administration and Monitoring System (NAPAMS) portal.
• Regulated stakeholders must notify NAFDAC and follow specific procedures when initiating a product recall.

The agency actively encourages consumers to utilize these official NAFDAC fake drug reporting channels in Nigeria, emphasizing that providing relevant information is crucial for investigations and identifying potential safety issues.

The National Agency for Food and Drug Administration and Control (NAFDAC) has established comprehensive channels for the Nigerian public to report concerns regarding pharmaceutical products. These mechanisms are designed to facilitate the reporting of suspected fake, substandard, or unregistered medicines, as well as adverse reactions experienced from drugs and other regulated medical items. The agency actively encourages consumers to utilize these official NAFDAC fake drug reporting channels in Nigeria, emphasizing that providing relevant information is crucial for investigations and identifying potential safety issues.

This proactive approach by NAFDAC underscores its commitment to public health and safety within the Nigerian pharmaceutical landscape. By empowering citizens to report suspected violations, the agency aims to enhance its oversight capabilities, ensuring that only safe and effective medical products are available for consumption. The various platforms cater to different types of concerns, streamlining the process for individuals to contribute to national pharmaceutical compliance reporting efforts.

For individuals who experience an unusual or adverse reaction after using medicines, vaccines, or other regulated medical products, NAFDAC provides several dedicated avenues to report adverse drug reactions NAFDAC. The primary digital tool for this is the NAFDAC MedSafety app, which is readily available for download on both the Google Play Store and the Apple App Store. In addition to the mobile application, reports can also be submitted via email to `pharmacovigilance@nafdac.gov.ng` or through the e-reporting platform accessible on NAFDAC’s official website.

When the concern relates to the authenticity or quality of a medical product, such as a suspected falsified, fake, substandard, or unregistered item, the agency directs the public to different specific channels. The NAFDAC Greenbook app serves as a key resource for this purpose and can also be downloaded from the Google Play Store and Apple App Store. Complementing the app, the Greenbook web platform at `greenbook.nafdac.gov.ng` offers an alternative online reporting method. For those preferring traditional communication, reports can be sent to `sf.alert@nafdac.gov.ng` or communicated via telephone at `0800-162-3322`. These diverse options ensure accessibility for all Nigerians to report suspected fake drugs.

Beyond reporting issues, NAFDAC also provides tools for consumers to verify NAFDAC product registration status, a critical step in ensuring product legitimacy. Individuals can confirm whether a product is officially registered with the agency by inputting its registration number into the NAFDAC Automated Product Administration and Monitoring System (NAPAMS) portal, found at `registration.nafdac.gov.ng`. The agency strongly advises consumers to utilize this portal to check a product's registration status before relying on its use, thereby contributing to robust Nigerian pharmaceutical compliance reporting.

For regulated stakeholders, such as pharmaceutical companies, NAFDAC has established clear guidelines for managing product recalls. When a product recall becomes necessary, stakeholders are mandated to notify NAFDAC and adhere to the agency's specified recall procedures. This notification should be formally addressed to the Director-General, routed through the Director of Post-Marketing Surveillance. Essential information required for such notifications includes the product name, its registration number, details of the manufacturer or marketing authorization holder, the expiry date, the specific reason for the recall, the batch number, distribution particulars, and the proposed recall action. These notifications can be submitted electronically via NAFDAC’s designated post-marketing surveillance channel or as hard copies at any NAFDAC office, forming a crucial part of the NAFDAC product recall procedure.

NAFDAC consistently emphasizes the significant role of public participation in maintaining the integrity of the nation's drug supply. The agency stresses the importance of providing as much relevant information and supporting evidence as possible when submitting a report through any of its channels. This detailed input is invaluable, as it directly assists NAFDAC in identifying potential safety concerns, thoroughly investigating products, and continuously improving its services.

For general inquiries or to seek clarification on any of the agency’s services, the public can reach NAFDAC by calling `0700-162-3322` or by sending an email to `reform@nafdac.gov.ng`. Further official information and services are also available on the agency’s main website, `nafdac.gov.ng`. These contact points reinforce NAFDAC's commitment to transparency and accessibility, fostering a collaborative environment where both consumers and stakeholders contribute to a safer pharmaceutical environment in Nigeria.

Compliance officers and legal counsel for pharmaceutical companies or healthcare providers in Nigeria must be aware of these official NAFDAC reporting channels and verification tools to ensure regulatory adherence, manage product recalls effectively, and mitigate legal liabilities related to substandard or falsified medical products.

Source: Original reporting via Healthwise